InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,252.22
(
0.26%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Bxofscidad

Send PM Follow Ignore
Followers 0
Posts 232
Boards Moderated 0
Alias Born 06/13/2010

Bxofscidad

Re: biotech_researcher post# 73407

Tuesday, 05/31/2016 4:43:14 PM

Tuesday, May 31, 2016 4:43:14 PM

Post# of 80490
The deal was made with Otsuka and announced on 12/23/14, Ariad received an upfront payment of 77.5 Million and will receive an additional milestone (announcement is silent as to the amount) when Ponatinib is approved for patients with resistant or intolerant Philadelphie-positive Leukemia. Trials for any other indications will be paid by Otsuka and if Ponatinib is approved for any other indications, Ariad to receive additional milestone payment for each such approval. Ariad also gets 'substantial" share of net sales of Ponatinib.



Barry
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up